Stick or twist: Everolimus for seizures in tuberous sclerosis complex during the COVID-19 pandemic.

Moloney, Patrick B; Delanty, Norman

Moloney, Patrick B; Delanty, Norman.

Moloney PB; FutureNeuro, the Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, Dublin, Ireland; Blackrock Clinic, Dublin, Ireland; Department of Neurology, Beaumont Hospital, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland. Electronic address: patrickmoloney@rcsi.com.
Delanty N; FutureNeuro, the Science Foundation Ireland Research Centre for Chronic and Rare Neurological Diseases, Royal College of Surgeons in Ireland, Dublin, Ireland; Department of Neurology, Beaumont Hospital, Dublin, Ireland; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland.

Seizure ; 91: 271-272, 2021 10.

Article in English | MEDLINE | ID: covidwho-1294233

Subject(s)

COVID-19; Tuberous Sclerosis; Everolimus/therapeutic use; Humans; Pandemics; SARS-CoV-2; Seizures/drug therapy; Seizures/epidemiology; Seizures/etiology; Tuberous Sclerosis/complications

Keywords

COVID-19; Everolimus; Tuberous sclerosis complex; Vaccination

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberous Sclerosis / COVID-19 Type of study: Observational study Topics: Long Covid Limits: Humans Language: English Journal: Seizure Journal subject: Neurology Year: 2021 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google